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To better understand the cellular target(s) of cyclosporin ac-
tion in psoriasis, we have studied the effects of syste'mic 
short-term (7 d), low-dose (3 - 7.5 mg/kg) cyclosporin A 
administration on the expression of the cytokines interleukin 
(IL)-8 and IL-1 fJ in psoriatic lesions. RNA blot hybridization 
analysis of pretreatment keratome biopsies revealed. that ex-
pression ofbo~h cyt~ki~e mRNAs v.:as.highly variable fr?m 
patient to patIent. Slglllficant covanatlOn of both cytokme 
rnRNA levels was noted (r = 0.86, P < 0.0001). However, 
there was no significant correlation between expression of 
either cytokine and clinical severity, as measured by the 
pretreatment Psoriasis Area and Severity Index (P ASI). IL-1 fJ 
protein levels measured by enzyme-linked immunosorbent 
assay (ELISA) were highly correlated with IL-1 fJ mRNA 
levels, indicating that the differences in transcript levels ac-
curately reflect differences in epidermal cytokine protein. 
T he effectiveness of orally administered cyclosporin A (CsA) as an antipsoriatic agent has been well docu-mented [1]. Because CsA appears to be a relatively specific immunosuppressive agent [2], its effective-ness in psoriasis has been cited as evidence for a central 
role of inunune system activation in the pathogenesis of this disease 
[3,4]. Ho'Wever, at sufficiently high concentrations (2-10 Ilg/ml), 
CsA also has significant anti proliferative effects upon cultured 
human and murine keratinocytes (reviewed in [5,6]), and skin tissue 
CsA levels approach this range after oral administration of effective 
antipsoriatic doses [7] . Therefore, in addition to its immunosup-
press ive actions, CsA might act directly to inhibit the proliferation 
of psoriatic keratinocytes. 
The psoriatic keratinocyte may also play an important role in the 
initiation and/or maintenance of cutaneous inflammation in psoria-
sis through the production of chemotactic and proinflammatory 
cytokines, adhesion molecules, and antigen-presenting molecules 
such as HLA-DR (reviewed in [6,8]). Because this phenomenon 
may in turn be elicited by exposure to immune system-derived cyto-
kines, such as interleukin (IL)-l, interferon (IFN)-y, and tumor 
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Signific.ant reductio~s in both cytokine transcripts and in 
IL-1 (lunmunoreactive protein were noted in the high ex-
pr~sslOn subgroup after 1 week of cyclosporin A therapy, 
pnor to detectable clinical improvement. In contrast to its 
pronounced effects on epidermal cytokine expression in vivo 
and ~he allo~eneic mixed lymphocyte reaction in vitro, cyclo-
sponne A dId not inhibit the induction of intercellular adhe-
sion mol.ecule (ICAM)-l or IL-8 mRNAs by cultured kerati-
nocytes In response to IL-1 fJ or the combination of tumor 
necrosis factor (TNF)-a and interferon (IFN)-y. These data 
suggest that .epidermal keratinocytes respond to signals pro-
duced by ~ctivated T cells by coordinate expression of multi-
ple cytokmes, and that cyclosporin A acts primarily through 
b.lockade ofT cells,. rather than through keratinocyte activa-
tIOn. Key words: Immunology/skin disease/interleukins/ 
ICAM-1/chemokines.j Invest Dermatol1 01 :761-766, 1993 
necrosis factor (TNF)-Cl', it becomes important to determine 
~hether the effec~s of CsA on keratinocyte cytokine production in 
111110 are exer~ed dIrectly upon the keratinocyte, or instead reflect a 
blockade of Immune system activation. 
CsA is an effective antipsoriatic agent at both high [1] and low [7] 
doses, although the rate of clearing is dose dependent. We have 
taken advantage of this observation to study the effects of short-
t~rm CsA tre~tme~lt on cytokine gene expression in keratome biop-
sIes of psorIatIc sk1l1 prior to detectable clinical improvement. This 
study had two major objectives: i) to determine whether reduced 
cytokine expression precedes clinical improvement, thus providing 
sO.me eVIdence ~or the ~:u-ticipation of epidermal cytokines in psori-
aSIs pathogeneSIs, and u) to determine whether the effects of CsA 
are exert.ed directly ?r indirectly on the psoriatic keratinocyte. To 
accomphsh these objectives, we performed Northern blot and en-
zyme-linked. im~unosorbent assay (ELISA) analysis of IL-1 p and 
IL-8 expressIOn 111 keratome biopsies before and after 1 week of 
low-dose C~A treatment. In addition, we compared the effects of 
CsA on psorIatIc leSIons in VitlO to its effects on the induction ofIL-8 
and intercellular adhesion molecule (ICAM)-l mRNAs by IL-1, 
IFN-y, an.d T~F-Cl' in cult~red keratinocytes. The results suggest 
~hat a~phficatl?n of cytokme signaling may occur via a pathway 
1I1volv1l1g kerat1l10cyte-denved IL-8 in psoriatic lesions ill VitlO. In 
addition, comparisou of ill VitlO and ill vitro results suggests that CsA 
exerts one or more indirect effect(s) upon the expression of kerati-
nocyte-derived cytokines in psoriasis, presumably by inhibiting the 
elaboratIon of actlvat1l1g slgnal(s) by immune and/or inflammatory 
cells. 
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MATERIALS AND METHODS 
Study Design and Tissue Procurement The cohort of 26 patients stud-
ied here was a subset of the 85 patients enrolled in a multidose CsA trial 
conducted at the University of Michigan (7). Patients received oral CsA at 
doses of3 mg/kg/d (nine patients), 5 mg/kg/d (12 patients), or 7.5 mg/kg/ 
d (one patient), or placebo consisting of olive oil and polyoxyethylated oleic 
glycerides (olive oil Labrafil base, four patients). Prior to and after 7 d of 
treatment, lesional buttocks or thigh skin was subjected to keratome biopsy 
at a depth of 0.2-0.4 mm using a Castroviejo keratome. Normal volunteers 
and psoriatics not treated with CsA were recrUited from the Southeast Mich-
igan area and the Department of Dermatology clinic population and biop-
sied in an identical fashion. All studies involving human subjects were ap-
proved by the Institutional Review Board of the University of Michigan, 
and informed consent was obtained from each patient. 
Cell Culture Primary cultures of normal human keratinocytes were pre-
pared as described [9) from keratome biopsies of adult volunteers. Subcul-
tures were expanded in keratinocyte growth medium (KGM; Clonetics, San 
Diego, CAl, and used in the second to fourth passage. Cells were pretreated 
for 2-16 h with CsA dissolved in dimethylsulfoxide vehicle (0.1 % final 
concentration), with triamcinolone acetonide (TAC) dissolved in 10% eth-
anol vehicle [10) (0.01 % final ethanol concentration) or with vehicle alone. 
The cells were then treated with either IL-l cr. (5-100 ng/ml; Dainippon, 
Osaka, Japan) or a combination ofTNF-cr. (20 ng/ml; Amgen, Thousand 
Oaks, CAl and IFN-y (100 U/ml; Collaborative Research, Bedford, MA). 
Cytokine stocks were prepared in sterile phosphate-buffered saline (PBS) 
and stored in small aliquots at -70'C prior to use. After 6 h of cyrokine 
treatment, cultures were harvested for RNA isolation as described below. 
RNA Isolation and Analysis RNA was prepared from snap-frozen kera-
tome biopsies by the guanidinium isothionate-cesium chloride technique as 
previously described [11) , except that cesium trifluoroacetate (Pharmacia, 
Piscataway, Nl) was used according to the manufacturer's instructions. 
RNA was isolated from keratinocytes using RNAzol (Tel-Test, Friends-
wood, TX) as directed by the manufacturer. Forty micrograms total kera-
tome RNA, or 20 /-Ig total keratinocyte RNA (determined by optical density 
[00],60) was electrophoretically separated on 1 % formaldehyde-agarose 
gels and transferred to derivatized nylon membrane (Zeta-Probe; Bio-Rad, 
Richmond, CAl. Blots were hybridized against 32P-labe led probes prepared 
as described below, and were quantitated using either a laser densitometer 
. [11) or a phosphorimager [12) and normalized to cyclophilin as previously 
described [11). 
Plasmids and Hybridization Probes Plasmid DNAs were prepared by 
alkaline lysis and precipitation in polyethylene glycol [13). cDNA inserts 
were prepared by digestion with appropriate restriction endonucleases fol -
lowed by electrophoresis in low-melting-temperature agarose gels. Inserts 
were 32P-labeled by random priming, and had a specific activity of 1- 4 X 
109 cpm//-Ig DNA. The IL-l p (14), lipocortin II l11), and cyclophilin (11) 
probes used in these experiments have been previously described. The IL-8 
probe was a 0.45-kilobase pair (kb) Eco Rl insert from the plasmid 
pMDNCF 2-1 0.5 (15), the ICAM-l probe was a 1.9-kb XbaI fragment 
containing the entire ICAM-l coding sequence derived from the plasmid 
pGICAM-l [16), and [he cel lular retinoic acid binding protein (CRABP)-Il 
probe was a 0.9-kb EcoRl fragment derived from a human skin fibroblast 
library (12). The 36B4 probe was a 0.7 -kb PstI fragment derived from p36B4 
[17), which has recently been shown to encode the human acidic ribosomal 
phosphoprotein PO [18). 
Data Analysis All keratome biopsy-derived RNA specimens were blotted 
and sequentially rehybridized in parallel, allowing the quantitative dara 
from a total of three blots to be pooled. IL-8, IL-l p, and CRABP-Il densi-
tometry or phosphorimager data were normalized to cyclophil in to control 
for differences in loading and RNA intactness. Statistical comparisons were 
made on the normalized data using analysis of variance as previously re-
ported [6J. 
ELISA Assay oflL-l cr. and p In a subset of patients, the week 0 and week 
1 keratome biopsy specimens were divided, a portion being used to prepare 
RNA and the remainder to assay IL-l immunoreactive protein levels. 
Aqueous extracts of snap-frozen keratomes were prepared using Dulbecco's 
PBS containing 0.03% polyethylene glycol, and immunoreactive IL-1 pwas 
measured using a commercially available kit (Cistron, Pine Brook Nj) as 
described (14). Immunoreactive IL-l cr. was quantified using an ELISA com-
posed of monoclonal anti - IL-l cr. and polyclonal rabbit anti - IL-l cr. (both 
from Dainippon, Osaka, japan) as described previously [14). 
Immunocytochemistry Portions of the same frozen keratome biopsies 
used to prepare RNA were mounted in OCT compound (Miles Diagnos-
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Figure 1. Clinical evaluation of study cohort. Closed circles, CsA-treated (22 
subjects). Opell circles, CsA vehicle (four subjects). Asterisks, statistical signifi-
cance at the 0.001 level compared to week 0 (pretreatment) . The p value at 
week 1 for the treated group was 0.1. This cohort is a subset of a previously 
published study (7), and these data are reprinted by permission of the N Engl 
J Med (324:277, 1991). 
tics, Elkhart, IN) and 6-/-1 cryostat sections were prepared, acetone-fixed, 
air-dried, blocked with 10% normal goat serum, decorated with HLel 
MoAb (anti-CD45, 1 :20 dilution, Becton-Dickinson, San jose, CA) , fol-
lowed by fluorescein isothiocyanate (FITC)-cOI~ugated affinity-purified 
goat anti-mouse IgG (1:80 dilution; Organon-Teknika-Cappel, Durham, 
NC) , and examined with a Nikon fluorescence microscope as previously 
described [14J. The dermis and epidermis of slides stained with either HLel 
or the IgGl kappa isotypecontrol MoAb MOPC 21 were evaluated by three 
blinded observers on a scale of 0, 1, or 2 for absent, moderate, or marked 
staining, respectively. 
Allogeneic Mixed Leukocyte Reaction (AMLR) Lymphocytes were 
isolated from peripheral blood of two healthy individuals by Ficoll -Hypaque 
centrifugation. Ten milliliters of blood were diluted with an equal volume of 
RPM! 1640 medium and layered over 15 ml ofHistopaque-l077 (Sigma, St . 
Louis, MO) and centrifuged for 30 min at 500 X g. The lymphocyte band a[ 
the interphase was collected, washed twice, and resuspended in RPM! 1640 
containing 10% human AB serum at 5 X 106 cells/m!. The two-way mixed 
lymphocyte reaction was initiated by mixing 100-/-11 aliquots of the cell 
suspension from each of the two individuals (50,000 ce lls each) in a round-
bottom 96-well plate. The mixed cells were treated with 1 /-II of a 200 X 
solution of CsA in DMSO, or a 1000 X solution ofTAC in 10% ethanol. 
90% sterile water [10) to obtain the desired final concentration, or vehicle 
alone. Triplicate wells were used for each concentration of drug. The cells 
were incubated at 37'C in a humidified incubator under 5% CO2, On day 6 
the cells in each wel l were treated with 10 /lCi of lH-thymidine and incu-
bated for another 18 h. The ce lls were transferred to filters using a cell 
harvester and washed with ethanol, and 3H-thymidine incorporation was 
determined by scintillation counting. 
RESULTS 
Clinical Evaluation After 1 week of CsA therapy (3-7.5 mg/ 
kg/d), there was no significant difference in clinical severity relative 
to baseline, as evidenced by the Psoriasis Area and Severity Index 
(PAS I) [19]. However, with prolonged therapy, significant clinical 
improvement w as seen in this cohort of patients by 2 weeks (Fig 1, 
closed circles). In contrast, no improvement was obtained in the pla-
cebo group at any time point (Fig 1, open circles). 
Heterogeneity of Cytokine Expression In Vivo Figure 2 de-
picts a Northern blot comparison ofIL-8, CRABP-ll, and cyclophi-
lin mRNA levels in keratome biopsy specimens from normal and 
psoriatic individuals. Note that IL-8 transcripts (approximately 
1.8 kb) are undetectable in normal epidermis , but are elevated in 
most psoriatic les ions, albeit to variable extents. This variability was 
not due to variations in mRNA loading or intactness, as expression 
of cyclophilin was very similar in all samples, (Fig 2, boltom pa"e~ . 
except for one normal sample and one psoriasis sample that suffer 
RNA degradation during processing (lall e 7, normal, and la lle 4, 
psoriasis) . Moreover, expression of CRABP-ll transcripts ( - 1.4 
I 
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Figure 2. Northern blot analysis of IL-B, CRABP-II, and cyclophilin 
mRN A levels in keratome biopsies of normal and psoriatic skin. Re-hybridi-
zations of the same blot are shown. Each lalle, RNA extracted from a differ-
ent individual. Mobilities of ribosomal RNAs are indicated to tlie lift. Por-
tions of the results shown in the middle and lower pallels have been published 
previously [11] and are included here for comparison only. 
kb) was increased to nearly the same extent in all the psoriatic 
samples (Fig 2, middle panel). 
As previously reported [14), low levels of IL-l p mRNA are 
detectable by Northern blotting in some but not all psoriatic lesions 
(Fig 3). In pretreatment specimens in wh.ich IL-8 mRNA I~ve ls 
Were increased, IL-l p mRN A tended to be 111creased as well (Fig 3) . 
The autoradiographic data from the 12 subjects shown in Fig 3 and 
from an additional 14 subjects not shown were quantitated by den-
sitometry or phosphorimager and normalized to cyclophilin. As 
expected on the basis of inspection of the blots shown in Fig 3, 
pretreatment IL-l P and IL-8 mRNA levels were highly correlated 
(r = 0.86, P < 0.0001, Fig 4). 
Figure 4 also demonstrates quantitatively that pretreatment IL-l 
Pand IL-8 mRNA levels were substantially variable from patient to 
patient. To determine whether this variability in cytokine expres-
sion might be correlated with the degree of infiltration by immune/ 
inflammatory cells, a semiquantitative analysis of HLel immuno-
fluorescent staining was performed in cryostat sections prepared 
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Figure 3. Northern blot analysis of CsA effects on cytokine mRNA levels 
In psoriatic skin. Re-hybridizations of two different blots are shown. Top 
/'llnel, EtBr, ethidium bromide-stained gel. Lift, mobilities of ribosomal 
RNAs. In all other palleis, the hybridization probe is indicated to the right. 
Cyclo, cyclophilin; lipo II, lipocortin II . 
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Figure 4. Correl.ation ofIL-l p and IL-B mRNA levels in pretreatment skin 
samples. Each f 0ltzt, a different individual, assayed at week 0 of the CsA 
study. The IlIze II1dlcates the best fit to the data after linear regression analysis 
(r = 0.B6, P < 0.0001). 
from pretrea~me.nt biopsie.s of four individuals displaying the high-
est, and five lI1dlVlduals displaying the lowest, expression of IL-8. 
There was no detectable difference in the degree of HLel staining 
1I1 the two groups (data not shown). In addition, there was no 
correlatIOn be.tw~en t!le pretreatment expression of these two cyro-
bnes and the mltlal disease severity or eventual clinical outcome as 
assessed by the PAS I score at weeks 0,1,4, and 6 (data not show~) . 
C?ordinate Reduction of Cytokine Expression by CsA In 
VIVO The Northern blots shown in Fig 3 demonstrate that IL-8 
m~NA levels were markedly reduced after 1 week of CsA therapy 
(Fig 3, second pa~lel from top) . IL-l p mRNA levels appeared to be 
reduced ~y CsA.1I1 a coordinate fas hion (Fig 3, third panel from top). 
~ome patients displayed a reduction in the intensity of the cyclophi-
1111 control gene after 1 week of CsA therapy. This appeared to be 
du~ ~o red~ced RNA 1I1tac tness, as detected by ethidium bromide 
sta1l1111g (Fig 3, top panel) . This overall decrease in RNA intactness 
after ~sA was. reflec~ed in similar reductions in a separate control 
gene, hpocort1l1 2 (Fig 3, bottom panel). These variations were con-
trolled for b~ normalizing the quantitative data to cyclophilin. Even 
after normahzatlon, marked and sign.ificant reductions in both IL-8 
(81.2%, p < 0.02 by two-sided paired t test) and IL-l p (85 .8%, 
P < 0.015) mRNA levels were observed (Fig 5). In contrast, only a 
shght decrease 111 CRABP-II mRNA was observed (8.7%, p = 
0.05) . 
Correlation ofIL-tp mRNA and Protein Levels To assess the 
relationship between cytokine mRNA and protein levels IL-l ll' 
and ~ protein levels were measured by ELISA. IL-l fJ mR'NA and 
protell1levels measured pnor to CsA treatment were highly corre-
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Figure 5. Quantitation of CsA effects on IL-t p, IL-B, and CRABP-I1 
mRN A levels in psoriatic skin. Opel/ bars, week 0; closed bars, week 1. Error 
bars, SEM (n = 22). 
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Figure 6. Effects of CsA on IL-l a and IL-l p immunoreactive protein (in 
pg IL-l per mg keratome extract protein) in psoriatic skin. Week 0 versus 
week 1 p values: IL-l p, P = 0.004, IL-l a, p = 0.77. Error bars, SEM. 
lated (r = 0.75, P = 0.0001, n = 22). Although IL-l a transcripts 
are undetectable by Northern blotting under these conditions [14], 
IL-t a protein was detectable, and pretreatment IL-l a and P pro-
tein levels also proved to be correlated (r = 0.52, P < 0.05, n = 15). 
However, CsA treatment had no effect on IL-l a protein levels, 
whereas IL-l P protein, like IL-t P mRNA, was significantly re-
duced after 1 week (p < 0.004, Fig 6). 
CsA Effects on Cytokine Expression in Cultured Keratinoc-
ytes Figure 7 shows results representative of 12 experiments in 
which secondary cultures of normal human keratinocytes were 
propagated in serum-free KGM, pretreated either with CsA, TAC, 
or vehicle control, then subjected to treatments with various cyto-
kines. CsA at doses up to 10 11M (12,000 ngjml) and TAC at doses 
up to 111M (300 ng/ml) were completely ineffective in inhibiting 
the induction of IL-8 mRNA in response to IL-t a or IFN-y plus 
TNF-a (Fig 7, and additional experiments not shown). Variation of 
'the time of CsA pretreatment from 2-24 h had no effect on the 
results (data not shown). As previously reported [20-22], ICAM-l 
mRNA was induced markedly by IFN-y plus TNF in keratinocytes 
grown in KGM. However, pretreatment with either CsA or TAC 
also had no effect on these responses (Fig 7). IL-l treatment at 100 
U jml produced only a low and variable ICAM-! mRNA response, 
which appeared to be potentiated slightly by CsA (Fig 7 and data not 
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Figure 7. Effects of CsA and TAC on cytokine-stimulated IL-S and 
ICAM-l mRNA levels in cultured human keratinocytes. Re-hybridizations 
of the same blot are shown. Upper pauei, mixture ofICAM-l and lL-S probes 
of comparable specinc and total activity. Lower panel, cyclophilin probe. 
Mobilities of ribosomal RNAs are indicated to the left, and probes to the 
right. Pretreatment with CsA and TAC was for 16 h prior to 6 h of treat-
ment with the agonists indicated by uumber above tl.ejigure. I, no treatment; 
2, IL-l a (100 ng/ml); 3, IFN-y (100 U/ml) plus TNF-a (20 ng/ml). 
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Figure 8. Dose response of inhibition of the two-way AMLR by CsA and 
TAC. A) Response to CsA. Mean ± SEM of triplicate determinations from 
one experiment are shown. This experiment was repeated with very similar 
results on two different lots of CsA powder. B) Response to TAC. Mean ± 
SEM of triplicate determinations are shown. This experiment was repeated 
with vety similar results. ICso values given in the text were determined by 
interpolation from the mean values. 
shown}. In additional experiments designed to vary the state of 
keratinocyte differentiation, cells were cultured in 2 mM CaCI2 for 
one passage or allowed to grow to postconfluence prior to CsA 
pretreatment and cytokine challenge. However, neither of these 
maneuvers had any effect on the results (data not shown). The lack 
of effect of T AC was not due to the presence of hydrocortisone in 
KGM, as its exclusion from the medium for one passage prior to 
assay had no effect on the results (data not shown). 
In contrast to its lack of effect on keratinocytes, the same CsA 
preparation potently inhibited the two-way AMLR with an ICso of 
approximately 20 ngjml (Fig 8A). Similarly, TAC inhibited the 
AMLR with an lCso of < 1 nM ( < 0_3 ngjml) (Fig 8B) . Both 
agents gave nearly complete inhibition of the AMLR at concentra-
tions that were ineffective for inhibition of keratil10cyte responses 
(compare Figs 7 and 8) . 
DISCUSSION 
The strong association of psoriasis with certain HLA types [23], as 
well as the effectiveness of several anti psoriatic therapies that share 
immunosuppression as a common feature (e.g., CsA, corticoste-
roids, methotrexate, UVB, and PUV A [1,24 - 26]), clearly implicate 
abnormalities of the immune system in the pathogenesis of psoria-
sis. CsA and corticosteroids have relatively little effect on keratino-
cyte proliferation in vitro at clinically relevant doses [5,6,10]' sug· 
gesting that psoriatic epidermal hyperplasia is not autonomous but 
rather a response to immune system activation. This concept raises 
the question of whether the keratinocyte is merely an "innocent 
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bystander," or in fact plays an active role in the initiation and/or 
maintenance of the psoriatic lesion. 
Keratinocytes may participate in the pathogenesis of psoriasis 
through the generation of chemotactic signals for immune/inflam-
matory cells [6,8]. IL-8 is one candidate for such a signal, as it is 
known to be chemotactic for neutrophils ill vivo [27,28] and for 
lymphocytes ill vitro [29], and IL-8 RNA and protein are increased in 
psoriatic lesions ([.30 - 32],. Fig 2). I.L-.8 is ~ member of.the int~rcrine 
a family of cytokmes, wluch are dlstmgUlshed by their localIzation 
on chromosome 4q21 [33,34] . These cytokines are often considered 
as secondary response elements of the cytokine cascade, because 
several of them share the property of inducibility by other (primary) 
cytokines (namely IL-1 and TNF-a) in a variety of cell types 
[33,34]. IL-8 also has the properties of a secondary cytokine in 
cultured keratinocytes, as its expression is induced by IL-1 [21] or by 
TNF-C\' acting in concert with IFN-y [20]. . 
In studying the effect of CsA on epidermal cytokine expression in 
psoriasis lesions, we analyzed keratome biopsies after 1 week of 
therapy, when no significant improvement in clinical status could 
be detected. This time interval was selected to avoid the confound-
ing effect of overall reduction in lesion severity on the results. In this 
study, IL-8 and IL-1 p were variably but coordinately expresse~ in 
pretreatment biopsies (Fig 3), resulting in a significant correlatIOn 
between pretreatment IL-1 p and IL-8 mRNA levels (Fig 4). 
Curiously, neither differences in clinical status nor in the total num-
ber of bone marrow-derived inflammatory cells in the lesions could 
explain the observed variability in cytokine mRNA levels. After 1 
week, both cytokine transcripts were markedly reduced (81- 85%), 
whereas CRABP-II transcripts were reduced only slightly (8%) (Fig 
5). Taken together with the high correlation in pretreatment IL-1 p 
and IL-8 values, their coordinate reductions early in CsA therapy 
strongly suggest that both cytokine responses are affected by a com-
mon proximal stimulus. which is inhibited by CsA. . 
It is worth noting that all patients, and not just those with high 
levels of IL-8/IL-1 p expression, rapidly improved with CsA ther-
apy. This suggests ~ith~r that CsA.may inhibit distinct signal trans-
duction pathways m different patients, or that the IL-8/IL-1 p re-
sponse is variable in space and/or time and is therefor~ not always 
detected. We favor the latter explanation, because the differences 111 
pretreatment cytokine mRNA levels between patients could n~t be 
accounted for in terms of the total numbers of bone marrow-denved 
cells in the biopsy specimen. In further support of this concept, one 
of four placebo-treated patients showed a large increase in IL-8 and 
IL-l p mRNA between week 0 and week 1 (data not shown). 
Given the relative specificity of CsA for T cells [2], the simplest 
explanation for these resul ts is that CsA inhibits the ability of acti-
vated T cells to produce signals leading to increased keratinocyte 
cytokine expression, but does not directly inhibit the ability ofkera-
tinocytes to respond to such signals. To test this hypothesis, we 
studied the effects of CsA on IL-8 expression by cytokine-stimu-
lated cultured keratinocytes. We focused on IL-8, rather than IL-l 
p, because the high levels ofIL-8 detectable in some lesions indicate 
that the bulk of the IL-8 expression in psoriatic lesions is occurring 
in keratinocytes. Although IL-8 can be expressed in a variety of cell 
types found in the skin, including T cells [35], macrophages [3~], 
and fibroblasts [21], its expression at high levels by keratinocytes 111 
psoriasis has been convincingly demonstrated [32]. In contrast, IL-1 
p mRN A levels in psoriatic lesions are near the lo.wer limi~ of de tec-
rability of the Northern blot assay [14], which IS approximately 1 
copy per cell under the conditions used [37]. Thus, it is unclear 
whether the IL-1 p mRNA detected by Northern blotting in psoria-
sis lesions is keratinocyte derived. CsA was unable to inhibit cyto-
kine-stimulated IL-8 expression in cultured keratinocytes after ei-
ther CsA or TAC treatment, at concentrations far higher than those 
required to inhibit the l1~ixed lymphocyte response (Figs 7, 8) .. This 
result strongly reinforces the conclUSIOn that the keratmocyte IS not 
the direct target of CsA action in psoriasis. The inactivity of CsA in 
this regard was not limited to the IL-8 response, as the ICAM-1 
mRNA response to IFN-y plus TNF-a was unaffected, and the 
limited ICAM-1 response to IL-l was slightly potentiated (Fig 7). 
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These results are consistent with previous studies that show that at 
concentrations as high as 1- 5 ,ug/ml, CsA does not inhibit, and in 
fact may slightly potentiate, keratinocyte expression oOL-I, GM-
CSF, IP-10, and transforming growth factor (TGF)-a [38,39] . 
Regardmg the nature of the T-cell-derived signal(s), we specu-
late that limited expression of primary cytokine(s) either directly by 
T cells or by infiltrating macrophages and/or dendritic cells under 
the control of T cells might trigger the expression of IL-8 at much 
high.er levels. in nearby keratinocytes. This interpretation would be 
consl~tent With. the demons~ratlOn of clusters of IL-8 - expressing 
kerat1110cytes directly overlymg collections of leukocytes [32]. It is 
attractive to speculate that one of these primary cytokines might be 
IL-1 P; however, our previous studies of IL-l in psoriasis indicated 
that IL-l P extracted from psoriatic lesions lacked biologic activity 
[14]. Among many other possibilities, T -cell-derived IL-8 itself 
could be one of the signals linking T cells and keratinocytes. Thus, 
CsA ha~ been ~hown to inhibit the expression of IL-8 and several 
related Intercnne-a gene family members in T lymphocytes [35] 
but not In lfolonocytes [35,36] . Alternatively, the relevant signal for 
the productIOn of IL-8 in keratinocytes could be actual contact with 
T cells or macrophages themselves [40]. Preliminary reports have 
suggested that IL-8 can stimulate keratinocyte growth in organoty-
pIC ~ulture systems,' and limited effects of IL-8 on keratinocyte 
proltferatlOn have been observed under serum-free conditions [41]. 
~hether IL-~ and related cytokines such as gro-at directly con-
tnbute to psonatlc epidermal hyperplasia in villa remains to be deter-
mined. 
.The strong positive correlation between IL-1 P mRNA and pro-
tem levels before and after CsA therapy indicates that the low level 
of expressIOn detectable by Northern blotting is reflective of the 
a~ount o~IL~ 1 P actually present in psoriatic lesions. However, the 
biologiC slgmficance of these observations remains obscure, and 
review of the I~terature reveals many apparent inconsistencies in the 
le~els of cytokme mRNAs, proteins, and biologic activities in psori-
atic leSIOns [14,~2,36,42-45]. Potential explanations for these dis-
parate observations include: i) translation of unstable or rare 
mRNAs mto stable proteins; ii) antibody cross-reactions with other 
keratinocyte proteins; iii) differential biologic activities of intra- and 
extr~cellul~ ~ytokine pools; iv) the presence of specific and non-
speCific mhlbltory pr<:>teins; and v) the uptake of cytokines synthe-
Sized elsewhere by epidermal keratinocytes. Experimental evidence 
suppo.rts th.e conc.ept that the skin may serve as a depot for systemic 
cytokmes, mcludmg TNF-a [46] and IL-6 [47] . Moreover, proteins 
as large as bov111e serum albumin (molecular weight 69,000) can 
enter the epldermal .compartment from the circulation [48]. Addi-
tional careful investigations will be required to fully elucidate the 
cellular source(s) of epidermal cytokines ill villa. 
Taken together with results demonstrating the coordinate varia-
bility ~n all three forms of MGSA/ gro in psoriatic lesions and their 
:eductlOn after 1 ",:,eek of CsA treatment, t the results presented here 
ll1dlcate that multiple keratmocyte-derived cytokines are under co-
ordinate regulation in psorias is. perhaps by virtue of a shared signal 
transduction pathway.capable of responding to T-cell-derived sig-
nals. The reduction m ~L-8/gro chemotactic activity after CsA 
treatme.nt would beyredlcted to suppress further influx ofT cells 
and antlgen-presentmg cells [6,8], contributing to eventual resolu-
tion of the lesion. However. substantial clinical resolution required 
6-8 weeks of therapy (Fig 1), whereas cytokine expression levels 
were mar~edly reduced afte~ only 1 week (Figs 3, 5). It is possible 
that once 111ltlated, the keratll10cyte may be capable of sustaining a 
hyperproiIferauve response via CsA-insensitive autocrine mecha-
nisms, such as overexpression of the EGF-like growth factors 
• Reusch MK. Studtmann M. Schroeder J-M. Stichcrling M. Chris-
tophers E: NAP / interleukin 8 is a potent mitogcn for human kcratinocytcs 
ill lIitra (abstr). J Illvest Dermatal 95:460, 1990 
t Kojima T. Cromie MA. Fisher GJ. Voorhees JJ. Elder JT: Gro-a 
mRNA is selectively overexpressed in psoriatic epidermis and is reduced by 
cyclosporin A ill lIillO, but not in cultured keratinocytes. J hlVesr Dermarol 
101 :767 -772. 1993 (this issue) 
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TGF-a and amphiregulin [49-52]. In any case, these results 
strongly support the concept that esA acts rapidly but indirectly ~o 
reduce expression of IL-8 and IL-l P expressIOn by th.e ps~natlc 
keratinocyte in lIillo, and suggest a role for these cytokmes m the 
pathogenesis of psoriasis. 
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